Modeling of Intracerebral Vascularization After Extracorporeal Membrane Oxygenation in Children
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Feb 9, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how a treatment called extracorporeal membrane oxygenation (ECMO) affects blood flow in the brains of young children. ECMO is a temporary life-support technique used when a child has severe breathing or heart problems. Researchers will look at how blood circulation in the brain changes after ECMO is used and how different methods of repairing blood vessels can impact this circulation once the child is off the machine.
To participate in this study, children must be under 20 kg (about 44 pounds) and hospitalized in a pediatric intensive care unit. They should have required ECMO due to serious breathing or heart issues and need to be alive after the treatment. The study will involve a special imaging test called Magnetic Resonance Angiography (MRA) to visualize blood flow in the brain. Parents or guardians will be informed about the study and must agree to their child's participation. Overall, this research aims to improve understanding of how ECMO affects brain health in children, which could lead to better care in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For everyone :
- • 1. Information and non-opposition of holders of parental authority
- • 2. Newborn, infant and child \<20kg
- • 3. Hospitalization in pediatric and neonatal intensive care unit (PICU) of Trousseau Hospital
- • 4. Performing a Magnetic Resonance Angiography (MRA) as part of the treatment
- • For patients treated with ECMO: study population
- • 5. Hemodynamic or respiratory failure
- • 6. Requiring the use of extracorporeal circulation with jugulo-carotid cannulation
- • 7. Weaned alive off Extra corporeal membrane oxygenation (ECMO)
- • For patients with hypoxic-ischemic encephalopathy: control population
- • 8. hypoxic-ischemic encephalopathy diagnosed at birth
- Exclusion Criteria:
- • 1. Contraindication to MRA
- • 2. Opposition of holders of parental authority
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Sabine Irtan, MD, PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Garance Martin, MD
Study Director
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials